Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, 100191, China.
Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, 100191, China.
Sci Rep. 2024 Sep 27;14(1):22232. doi: 10.1038/s41598-024-72795-0.
Metabolic dysfunction-associated steatotic liver disease (MASLD) brings heavy clinical and economic burdens to patients worldwide. High fasting plasma glucose (HFPG) was proven to be an important modifiable risk factor. However, the global burden distribution of HFPG-attributable MASLD has not been fully studied. This study aimed to describe the epidemiological distribution and trends of the burden of HFPG-attributable MASLD worldwide. The data source was the 2021 Global Burden of Disease Study. Descriptive statistics were mainly conducted using disability-adjusted life years (DALYs) and deaths of HFPG-attributable MASLD from 1990 to 2021, as well as their age-standardized rates (ASRs) and population-attributable fractions. Subgroup analyses were conducted by region, age group, and sex. We found that 213.48 thousand DALYs and 10.02 thousand deaths in MASLD were attributable to HFPG worldwide in 2021, with an increase of 2.96 and 3.32 times compared with 1990, respectively. Over the past 32 years, age-standardized DALY rates (ASDRs) have fluctuated upward, reaching 2.45 per 100,000 people in 2021, with an increase of 81.21%. The ASDRs continued to rise in low, low-middle, and high social demographic index (SDI) regions, fluctuated upward at high levels in middle SDI regions, and were relatively low in high-middle SDI regions. People aged 50-69 accounted for the largest proportion of DALYs, while people over 70 had the largest increase of 3.73 times. Men had higher ASDRs, and the sex difference has been gradually expanding over the past 32 years, peaking at the age of 45-49. In conclusion, the burden of HFPG-attributable MASLD has continued to increase globally, with differences in geographical area, age, and sex distribution. HFPG, as a modifiable risk factor, should be given more importance. The implementation of targeted health intervention strategies is recommended for each country based on trends in the burden of HFPG-attributable MASLD.
代谢相关脂肪性肝病（MASLD）给全球患者带来了沉重的临床和经济负担。高空腹血糖（HFPG）已被证实是一个重要的可改变的危险因素。然而，HFPG 相关 MASLD 的全球负担分布尚未得到充分研究。本研究旨在描述全球 HFPG 相关 MASLD 的流行病学分布和负担变化趋势。数据来源是 2021 年全球疾病负担研究。主要采用残疾调整生命年（DALYs）和 HFPG 相关 MASLD 的死亡人数以及其年龄标准化率（ASR）和人群归因分数来进行描述性统计分析。通过地区、年龄组和性别进行亚组分析。结果发现，2021 年全球 MASLD 中有 21.348 个 DALY 和 10.020 个死亡归因于 HFPG，与 1990 年相比，分别增加了 2.96 倍和 3.32 倍。在过去的 32 年中，年龄标准化 DALY 率（ASDR）呈波动上升趋势，2021 年达到每 10 万人 2.45 例，增加了 81.21%。低、低中、高社会人口指数（SDI）地区的 ASDR 持续上升，中 SDI 地区的水平波动上升，高中 SDI 地区相对较低。50-69 岁人群占 DALY 比例最大，70 岁以上人群增幅最大，达 3.73 倍。男性的 ASDR 较高，且过去 32 年中性别差异逐渐扩大，在 45-49 岁时达到峰值。综上所述，HFPG 相关 MASLD 的负担在全球范围内持续增加，在地域、年龄和性别分布方面存在差异。HFPG 作为一个可改变的危险因素，应受到更多重视。建议各国根据 HFPG 相关 MASLD 的负担变化趋势，制定有针对性的健康干预策略。
